Efectos adversos cutáneos inmunorelacionados¿predictores de respuesta terapéutica de los inhibidores del punto de control inmunitario?
- Elena Lucía Pinto Pulido
- Miriam Fernández Parrado
- Francisco José Rodríguez Cuadrado
ISSN: 2171-9020
Datum der Publikation: 2023
Ausgabe: 4
Nummer: 61
Art: Artikel
Andere Publikationen in: MPG Journal
Zusammenfassung
The introduction of immune checkpoint inhibitors has revolutionized cancer treatment in recent years. We comment on a multicenter retrospective cohort study comparing the survival of oncology patients treated with these drugs who developed immune-related skin adverse effects with those who did not.
Bibliographische Referenzen
- Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. J Eur Acad Dermatol Venereol. 2022; 36(3):332-350. doi: 10.1111/jdv.17855.
- Tang K, Seo J, Tiu BC, et al. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol. 2022; 158(2):189-193. doi: 10.1001/jamadermatol.2021.5476.
- Zhang S, Tang K, Wan G, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study. J Am Acad Dermatol. 2023; 88(5):1024-1032. doi: 10.1016/j.jaad.2022.12.048.